Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase I/III Clinical Trial of Adsorbed Tetanus Vaccine
Sponsor: Beijing Minhai Biotechnology Co., Ltd
Summary
The study aimed to evaluate the safety and immunogenicity of an adsorbed tetanus vaccine in healthy individuals between 18 and 43 years of age.
Official title: A Randomized, Blinded, Parallel-Controlled Phase I/III Clinical Trial to Evaluate the Safety and Immunogenicity of Adsorbed Tetanus Vaccine in Healthy Individuals Aged 18-43 Years
Key Details
Gender
All
Age Range
18 Years - 43 Years
Study Type
INTERVENTIONAL
Enrollment
1240
Start Date
2024-02-29
Completion Date
2024-12-23
Last Updated
2026-08-03
Healthy Volunteers
Yes
Conditions
Interventions
Tetanus Toxoid (Adsorbed)
The study group's vaccines had been produced by Beijing Minhai Biotechnology Co., Ltd. Liquid formulation. 0.5 mL/vial.
Tetanus Toxoid (Adsorbed)
The manufacture of control group vaccines were Chengdu Olymvax Biopharmaceuticals Inc. Liquid formulation. 0.5 mL/vial.
Locations (1)
Guangdong Provincial Center for Diseases Control and Prevention
Guangzhou, Guangdong, China